Company intelligence / Profile preview

Urgo Medical

Ownership: Private
Employees: ~1500
Development stage: Commercial

Overview

Urgo Medical has a broad commercial portfolio of advanced wound care products with over 80 clinical and observational studies supporting their efficacy. The company’s Genesis program aims to develop artificial skin as a next-generation solution for hard-to-heal wounds. Products are widely used in hospitals and home health settings.

Therapeutic areas: OtherDermatology
Modalities: Wound dressings (including hydroconductive and lipidocolloid technologies)compression bandageswound cleansersartificial skin (cell-based therapy)
Industry: Consumable Medical Devices

Drug pipeline

5 assets

Vashe

Commercial

Indications: Wound cleansing, Wound irrigation

4 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with healthcare professionals/scientific bodiesFrance 2030 support for Genesis program

Beyond the preview

Go deeper on Urgo Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urgo Medical.

Explore the full profile